Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 673

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 4
Chunk 673
---
, the
    Company sold 152,000 shares of the Company’s common stock for aggregate gross proceeds of approximately $0.4 million. The
    Company’s ability to issue shares under the shelf registration statement on Form S-3 is limited by General Instruction I.B.6
    to Form S-3. On August 6, 2024, the Company filed a prospectus supplement to reduce the amount
    of shares registered under the prospectus for the ATM to $0.00 and to suspend the ATM program, but the ATM Agreement remains in full
    force and effect.

    c.
    On
    August 8, 2024, the Company completed a registered direct offering, pursuant to which the Company sold and issued to certain investors,
    including an officer of the Company, 1,643,837 shares of the Company’s common stock at a purchase price per share of $1.825.
    In addition, in a concurrent private placement, the Company also issued to the purchasers in the August 2024 Offering unregistered
    warrants to purchase 1,643,837 shares of the Company’s common stock (the “August 2024 Warrants”). The August 2024
    Warrants are immediately exercisable at an exercise price of $1.70 per share and expire five years from the date of issuance. The
    total net proceeds were approximately $2.5 million, after deducting placement agent and other offering expenses in the amount of
    approximately $0.5 million. In September 2024, the Company filed a registration statement to register the resale by the investors
    of the shares of common stock issuable upon exercise of the August 2024 Warrants. The registration statement was declared effective
    on September 20, 2024.

    d.
    On November 22, 2024, the
    Company completed a registered direct offering, pursuant to which the Company sold and issued to certain investors, including an
    officer of the Company, 1,817,017 shares of the Company’s common stock at a purchase price per share of $1.175. In addition,
    in a concurrent private placement, the Company also issued to the purchasers in the November 2024 Offering unregistered warrants
    to purchase 1,817,017 shares of the Company’s common stock (the “November 2024 Warrants”). The November 2024 Warrants
    are immediately exercisable at an exercise price of